000088735912/312024Q3FALSEhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesvcel:productvcel:segmentvcel:pharmacyxbrli:pureutr:sqftvcel:renewal_optioniso4217:USDutr:sqft00008873592024-01-012024-09-3000008873592024-10-3100008873592024-09-3000008873592023-12-3100008873592023-01-012023-09-3000008873592024-07-012024-09-3000008873592023-07-012023-09-300000887359us-gaap:CommonStockMember2023-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000887359us-gaap:RetainedEarningsMember2023-12-310000887359us-gaap:RetainedEarningsMember2024-01-012024-03-3100008873592024-01-012024-03-310000887359us-gaap:CommonStockMember2024-01-012024-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000887359us-gaap:CommonStockMember2024-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000887359us-gaap:RetainedEarningsMember2024-03-3100008873592024-03-310000887359us-gaap:RetainedEarningsMember2024-04-012024-06-3000008873592024-04-012024-06-300000887359us-gaap:CommonStockMember2024-04-012024-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000887359us-gaap:CommonStockMember2024-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000887359us-gaap:RetainedEarningsMember2024-06-3000008873592024-06-300000887359us-gaap:RetainedEarningsMember2024-07-012024-09-300000887359us-gaap:CommonStockMember2024-07-012024-09-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000887359us-gaap:CommonStockMember2024-09-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000887359us-gaap:RetainedEarningsMember2024-09-300000887359us-gaap:CommonStockMember2022-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000887359us-gaap:RetainedEarningsMember2022-12-3100008873592022-12-310000887359us-gaap:RetainedEarningsMember2023-01-012023-03-3100008873592023-01-012023-03-310000887359us-gaap:CommonStockMember2023-01-012023-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000887359us-gaap:CommonStockMember2023-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000887359us-gaap:RetainedEarningsMember2023-03-3100008873592023-03-310000887359us-gaap:RetainedEarningsMember2023-04-012023-06-3000008873592023-04-012023-06-300000887359us-gaap:CommonStockMember2023-04-012023-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000887359us-gaap:CommonStockMember2023-06-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000887359us-gaap:RetainedEarningsMember2023-06-3000008873592023-06-300000887359us-gaap:RetainedEarningsMember2023-07-012023-09-300000887359us-gaap:CommonStockMember2023-07-012023-09-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000887359us-gaap:CommonStockMember2023-09-300000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000887359us-gaap:RetainedEarningsMember2023-09-3000008873592023-09-300000887359us-gaap:FixedPriceContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2024-07-012024-09-300000887359us-gaap:FixedPriceContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2023-07-012023-09-300000887359us-gaap:FixedPriceContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2024-01-012024-09-300000887359us-gaap:FixedPriceContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2023-01-012023-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2024-07-012024-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2023-07-012023-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2024-01-012024-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2023-01-012023-09-300000887359us-gaap:FixedPriceContractMembervcel:ProviderorFacilityMembervcel:ImplantsMember2024-07-012024-09-300000887359us-gaap:FixedPriceContractMembervcel:ProviderorFacilityMembervcel:ImplantsMember2023-07-012023-09-300000887359us-gaap:FixedPriceContractMembervcel:ProviderorFacilityMembervcel:ImplantsMember2024-01-012024-09-300000887359us-gaap:FixedPriceContractMembervcel:ProviderorFacilityMembervcel:ImplantsMember2023-01-012023-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2024-07-012024-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-07-012023-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2024-01-012024-09-300000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-01-012023-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2024-07-012024-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2023-07-012023-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2024-01-012024-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:BiopsyKitsMember2023-01-012023-09-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2024-07-012024-09-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2023-07-012023-09-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2024-01-012024-09-300000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2023-01-012023-09-300000887359vcel:MACIImplantsAndKitsMember2024-07-012024-09-300000887359vcel:MACIImplantsAndKitsMember2023-07-012023-09-300000887359vcel:MACIImplantsAndKitsMember2024-01-012024-09-300000887359vcel:MACIImplantsAndKitsMember2023-01-012023-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2024-07-012024-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2023-07-012023-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2024-01-012024-09-300000887359us-gaap:SalesChannelDirectlyToConsumerMembervcel:EpicelMember2023-01-012023-09-300000887359vcel:ProviderorFacilityMembervcel:NexoBridMember2024-07-012024-09-300000887359vcel:ProviderorFacilityMembervcel:NexoBridMember2023-07-012023-09-300000887359vcel:ProviderorFacilityMembervcel:NexoBridMember2024-01-012024-09-300000887359vcel:ProviderorFacilityMembervcel:NexoBridMember2023-01-012023-09-300000887359us-gaap:MachineryAndEquipmentMember2024-09-300000887359us-gaap:MachineryAndEquipmentMember2023-12-310000887359us-gaap:FurnitureAndFixturesMember2024-09-300000887359us-gaap:FurnitureAndFixturesMember2023-12-310000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2024-09-300000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2023-12-310000887359us-gaap:LeaseholdImprovementsMember2024-09-300000887359us-gaap:LeaseholdImprovementsMember2023-12-310000887359us-gaap:ConstructionInProgressMember2024-09-300000887359us-gaap:ConstructionInProgressMember2023-12-310000887359us-gaap:LicensingAgreementsMember2024-09-300000887359us-gaap:LicensingAgreementsMember2023-12-310000887359us-gaap:LicensingAgreementsMember2024-07-012024-09-300000887359us-gaap:LicensingAgreementsMember2024-01-012024-09-300000887359us-gaap:LicensingAgreementsMember2023-07-012023-09-300000887359us-gaap:LicensingAgreementsMember2023-01-012023-09-300000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-280000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2023-04-300000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2023-06-010000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2023-06-012023-06-010000887359vcel:A25NetworkDriveBurlingtonMassachusettsMembersrt:MinimumMember2023-06-012023-06-010000887359vcel:A25NetworkDriveBurlingtonMassachusettsMembersrt:MaximumMember2023-06-012023-06-010000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2024-09-300000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-012022-01-310000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-07-292022-07-290000887359us-gaap:CommercialPaperMember2024-09-300000887359us-gaap:CorporateDebtSecuritiesMember2024-09-300000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000887359us-gaap:ShortTermInvestmentsMember2024-09-300000887359vcel:LongtermInvestmentsMember2024-09-300000887359us-gaap:CommercialPaperMember2023-12-310000887359us-gaap:CorporateDebtSecuritiesMember2023-12-310000887359us-gaap:USGovernmentDebtSecuritiesMember2023-12-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000887359us-gaap:ShortTermInvestmentsMember2023-12-310000887359vcel:LongtermInvestmentsMember2023-12-3100008873592023-01-012023-12-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2024-09-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2024-09-300000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310000887359us-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000887359us-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000887359us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2024-09-300000887359us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2023-12-310000887359us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-07-292022-07-290000887359us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-07-290000887359us-gaap:LineOfCreditMember2022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MinimumMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MaximumMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MinimumMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2022-07-292022-07-290000887359us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2024-07-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2024-01-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2024-07-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2023-07-012023-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2024-01-012024-09-300000887359vcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000887359us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000887359us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000887359us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000887359us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000887359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000887359vcel:MediWoundLtdMember2019-05-310000887359vcel:MediWoundLtdMember2022-12-310000887359vcel:MediWoundLtdMember2022-01-012022-12-310000887359vcel:MediWoundLtdMember2023-02-012023-02-280000887359vcel:MediWoundLtdMember2019-05-012019-05-31



美国证券交易所(SEC)
华盛顿特区20549
 表格 10-Q
 
☒     根据1934年证券交易法第13或15(d)条递交的季度报告
 
截止至季度末：  2024年9月30日
或者
☐        根据《1934年证券交易法》第13或15(d)条规定的过渡报告
 委员会文件号 001-35280
 
Vericel 公司
(根据其章程规定的注册人准确名称)
税号38-0593940 94-3096597
（设立或组织的其他管辖区域） （纳税人识别号码）
 
64 Sidney Street
剑桥, 万事达 02139
（总部地址，包括邮编）

公司电话，包括区号：(617) 588-5555 

根据该法案第12（b）条规定注册的证券: 
股份种类的名称交易标志CubeSmart的每个交易所的名称
普通股（无面值）请勾选以下项目。 (1) 在过去的12个月内（或注册人必须提交此类报告的较短期间内）是否已提交证券法规第13或15(d)条要求提交的所有报告; 以及(2) 在过去的90天内是否已受到此类提交要求的约束。纳斯达克

请勾选以下项目。 根据证券交易所法案S-T规则（本章节第232.405条），注册人是否已经在过去的12个月（或注册人必须提交此类文件的较短时间内）以电子方式提交了每个交互式数据文件。 Yes x 否o
 
请通过复选标记表示，注册者在过去12个月内（或注册者需要提交此类文件的较短期间内）是否已根据S-t法规第405条（本章第232.405条）要求提交过每个交互数据文件。 Yes x 否o
 
请用复选标记表示公司是否为大型加速申报人、加速申报人、非加速申报人、较小报告公司或新兴成长公司。请参阅《交易所法》规则120亿.2中对“大型加速申报人”、“加速申报人”、“较小报告公司”和“新兴成长公司”的定义。
大型加速报告人☒加速文件提交人☐
非加速文件提交人☐较小的报告公司☐
 新兴成长公司☐
如果是新兴成长型企业，请勾选复选标记，表明注册者已选择不使用延长过渡期来符合根据证券交易法第13(a)条规定提供的任何新财务会计准则。 o

请勾选指示是否注册人是壳公司（如交易所法规规则120亿.2所定义）。是☐ 否x

截至2024年10月31日， 49,358,408 普通股股票，每股无面值，尚未流通。

1
目录
vericel 公司
 第10-Q表格季度报告
 目录
 
  页面
 第一部分-财务信息 
第 1 项。
财务报表（未经审计）：
 
 
 
 
第 2 项。
第 3 项。
第 4 项。
第二部分 — 其他信息
第 1 项。
第 1A 项。
第 2 项。
第 3 项。
第 4 项。
第 5 项。
第 6 项。
2
目录

第一部分 - 财务信息
 

项目1。基本报表（未经审核）

Vericel 公司
简明合并资产负债表
（未经审计，金额以千计）

 九月三十日,12月31日,
 20242023
资产  
流动资产：  
现金及现金等价物$53,681 $69,088 
受限现金16,669 17,778 
短期投资48,053 40,469 
应收账款（扣除呆账准备金$47,996）12 和 $43）
48,479 58,356 
库存15,756 13,087 
其他资产7,882 6,853 
总流动资产190,520 205,631 
资产和设备，净值88,413 41,635 
无形资产, 净额6,406 6,875 
使用权资产71,561 73,462 
所有基金类型投资32,895 25,283 
其他长期资产610 771 
资产总额$390,405 $353,657 
负债及股东权益  
流动负债:  
应付账款$20,884 $22,347 
应计费用14,343 17,215 
经营租赁负债流动部分6,119 6,187 
流动负债合计41,346 45,749 
经营租赁负债91,344 81,856 
其他长期负债243 100 
负债合计132,933 127,705 
承诺和 contingencies (注12)
股东权益：  
无面值普通股；已授权股数 — 75,000；已发行及流通股数 — 49,265 和 47,829 的坏账准备
669,735 629,229 
累计其他综合收益 (损失)359 (100)
累积赤字(412,622)(403,177)
股东权益合计257,472 225,952 
负债和股东权益总计$390,405 $353,657 

简化合并资产负债表附注是这些报表的一个组成部分。

3
目录
Vericel 公司
简明合并利润表
（未经审计，金额以千为计数，除每股数据外）
 
 截至9月30日的三个月截至9月30日的九个月
 2024202320242023
产品销售额，净额$57,905 $45,581 $161,848 $132,520 
总收入57,905 45,581 161,848 132,520 
产品销售成本16,252 14,973 48,240 45,451 
毛利润41,653 30,608 113,608 87,069 
研究和开发6,093 5,676 19,874 16,141 
销售、一般和管理38,025 29,989 107,694 90,123 
运营费用总额44,118 35,665 127,568 106,264 
运营损失(2,465)(5,057)(13,960)(19,195)
其他收入（支出）：   
利息收入1,578 1,262 4,850 3,196 
利息支出(154)(150)(460)(444)
其他收入（支出）140 (1)125 (18)
其他收入总额1,564 1,111 4,515 2,734 
所得税前亏损(901)(3,946)(9,445)(16,461)
所得税优惠— (286)— (286)
净亏损$(901)$(3,660)$(9,445)$(16,175)
每股普通股净亏损：
基本款和稀释版$(0.02)$(0.08)$(0.19)$(0.34)
已发行普通股的加权平均值：
基本款和稀释版49,085 47,649 48,639 47,537 

简化合并资产负债表附注是这些报表的一个组成部分。

4
目录
Vericel 公司
综合损失简明合并财务报表
（未经审计，金额以千为单位)

 截至9月30日的三个月截至9月30日的九个月
 2024202320242023
净亏损$(901)$(3,660)$(9,445)$(16,175)
其他综合收益（亏损）：
未实现的投资收益632 158 459 515 
综合损失$(269)$(3,502)$(8,986)$(15,660)

简化合并资产负债表附注是这些报表的一个组成部分。

5
目录
Vericel 公司 
股东权益基本报表摘要
（未经审计，金额以千计）

普通股其他综合收益（损失）累计赤字股东权益合计
股份金额
2023年12月31日的余额47,829 $629,229 $(100)$(403,177)$225,952 
净损失— — — (3,862)(3,862)
股票补偿费用— 9,834 — — 9,834 
股票期权行权487 6,779 — — 6,779 
员工股票购买计划下发行的股票9 247 — — 247 
以发行股票方式支付受限股单位归属权265 — — — — 
员工税金代扣而暂扣的受限股(101)(4,909)— — (4,909)
投资未实现亏损— — (145)— (145)
2024年3月31日的余额48,489 $641,180 $(245)$(407,039)$233,896 
净损失— — — (4,682)(4,682)
股票补偿费用— 9,520 — — 9,520 
股票期权行权329 4,020 — — 4,020 
员工股票购买计划下发行的股票14 414 — — 414 
为限制股单位归属发行股份34 — — — — 
扣留的限制性股票用于员工税务扣缴(4)(163)— — (163)
投资未实现亏损— — (28)— (28)
2024年6月30日余额48,862 $654,971 $(273)$(411,721)$242,977 
净损失— — — (901)(901)
股票补偿费用— 9,224 — — 9,224 
股票期权行权382 5,442 — — 5,442 
员工股票购买计划下发行的股票9 353 — — 353 
用于限制性股票单位解禁的股票发行16 — — — — 
员工税款代扣而暂扣的限制性股票(4)(255)— — (255)
投资未实现收益— — 632 — 632 
2024年9月30日余额49,265 $669,735 $359 $(412,622)$257,472 


6
Table of Contents
Common StockAccumulated Other Comprehensive Gain (Loss)Accumulated DeficitTotal Shareholders’ Equity
SharesAmount
BALANCE, DECEMBER 31, 202247,253 $593,245 $(978)$(399,995)$192,272 
Net loss— — — (7,495)(7,495)
Stock-based compensation expense— 8,731 — — 8,731 
Stock option exercises132 2,009 — — 2,009 
Shares issued under the Employee Stock Purchase Plan11 216 — — 216 
Issuance of stock for restricted stock unit vesting183 — — — — 
Restricted stock withheld for employee tax remittance(72)(2,097)— — (2,097)
Unrealized gain on investments— — 342 — 342 
BALANCE, MARCH 31, 202347,507 $602,104 $(636)$(407,490)$193,978 
Net loss— — — (5,020)(5,020)
Stock-based compensation expense— 8,761 — — 8,761 
Stock option exercises68 889 — — 889 
Shares issued under the Employee Stock Purchase Plan18 384 — — 384 
Issuance of stock for restricted stock unit vesting26 — — — — 
Restricted stock withheld for employee tax remittance(3)(79)— — (79)
Unrealized gain on investments— — 15 — 15 
BALANCE, JUNE 30, 202347,616 $612,059 $(621)$(412,510)$198,928 
Net loss— — — (3,660)(3,660)
Stock-based compensation expense— 7,924 — — 7,924 
Stock option exercises50 787 — — 787 
Shares issued under the Employee Stock Purchase Plan13 329 — — 329 
Issuance of stock for restricted stock unit vesting8 — — — — 
Restricted stock withheld for employee tax remittance(3)(86)— — (86)
Unrealized gain on investments— $— $158 $— $158 
BALANCE, SEPTEMBER 30, 202347,684 $621,013 $(463)$(416,170)$204,380 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.


7
Table of Contents

VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

 Nine Months Ended September 30,
 20242023
Operating activities:  
Net loss$(9,445)$(16,175)
Adjustments to reconcile net loss to net cash flows from operating activities:  
Depreciation and amortization expense4,027 3,483 
Stock-based compensation expense28,578 25,416 
Amortization of premiums and discounts on marketable securities(542)(788)
Amortization of debt issuance costs161 161 
Non-cash lease costs5,139 4,291 
Other25 18 
Changes in operating assets and liabilities:  
Inventory(2,669)3,365 
Accounts receivable9,877 6,810 
Other current assets(1,029)(627)
Accounts payable(1,639)360 
Accrued expenses(2,887)(2,562)
Operating lease liabilities6,182 1,408 
Other non-current assets and liabilities, net143 65 
Net cash provided by operating activities35,921 25,225 
Investing activities:  
Purchases of investments(52,612)(36,254)
Sales and maturities of investments38,416 60,890 
Expenditures for property and equipment(50,187)(12,178)
Purchases of intangible assets— (7,500)
Net cash (used in) provided by investing activities(64,383)4,958 
Financing activities:  
Net proceeds from common stock issuance 17,255 4,614 
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards(5,309)(2,262)
Other— (41)
Net cash provided by financing activities11,946 2,311 
Net (decrease) increase in cash, cash equivalents, and restricted cash(16,516)32,494 
Cash, cash equivalents, and restricted cash at beginning of period86,866 51,067 
Cash, cash equivalents, and restricted cash at end of period$70,350 $83,561 

8
Table of Contents
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(Unaudited, amounts in thousands)


Nine Months Ended September 30,
20242023
Supplemental disclosure of cash flow information:
Non-cash information:
Right-of-use asset and lease liability recognized$3,238 $36,022 
Additions to property and equipment included in accounts payable10,301 5,568 

Nine Months Ended September 30,
20242023
Reconciliation to amounts within the condensed consolidated balance sheets:
Cash and cash equivalents$53,681 $60,473 
Restricted cash16,669 23,088 
Total cash, cash equivalents, and restricted cash at end of period$70,350 $83,561 


The accompanying notes to condensed consolidated financial statements are an integral part of these statements.
9
Table of Contents
VERICEL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization

Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leading provider of advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI®, Epicel® and NexoBrid®.

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product that is indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Since MACI’s commercial launch, a treating surgeon has been able to use MACI to treat a patient through an open surgical procedure. In August 2024, however, the U.S. Food & Drug Administration (“FDA”) approved a supplemental Biologics License Application (“sBLA”) expanding the MACI indication to add instructions for the arthroscopic delivery of MACI to the product’s approved labeling. MACI Arthro™ allows surgeons to evaluate and prepare the cartilage defect site as well as deliver the MACI implant through small incisions using custom-designed arthroscopic instruments developed by the Company (“MACI Arthro instruments”). MACI Arthro became commercially available in the United States during the third quarter of 2024 and the Company began selling the MACI Arthro instruments at that time.

Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid (anacaulase-bcdb), a topically administered biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial-thickness and/or full thickness thermal burns. Following the FDA’s approval of a Biologics License Application for NexoBrid in December 2022, the Company began commercial sales of NexoBrid in the U.S. during the third quarter of 2023.

The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions. The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

The Ongoing Military Conflicts in the Middle East

In May 2019, the Company entered into exclusive license and supply agreements with MediWound, under which MediWound manufactures and supplies NexoBrid to the U.S. market on a unit price basis. MediWound develops and manufactures NexoBrid, in part, at its facilities in Yavne, Israel.

The Company continues to monitor the ongoing military conflicts in the Middle East region involving Israel, and the Company is in close communication with MediWound leadership. MediWound’s NexoBrid manufacturing operations are continuing and, as of the date of this disclosure, MediWound does not anticipate a material disruption to its ongoing supply of commercial NexoBrid to the United States. To the extent the conflicts in the Middle East region intensify or expand to include additional countries or militant groups and MediWound’s facilities in Israel are damaged or destroyed, travel to and from Israel is halted or inhibited, or significant key MediWound operational personnel are called to military service, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted. As of the date of this report, the Company maintains an ample supply of NexoBrid at its U.S.-based third-party logistics provider.

Liquidity

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2024, the Company had an accumulated deficit of $412.6 million and had a net loss of $9.4 million during the nine months ended September 30, 2024. The Company had cash and cash equivalents of $53.7 million and investments of $80.9 million as of September 30, 2024. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the
10
Table of Contents
Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation, the loss of which could have a negative effect on its operations and liquidity. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high-credit-quality financial institutions. The Company has not experienced any losses on these deposits; however, no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.

2. Basis of Presentation

The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.

The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses.

The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 29, 2024 (“Annual Report”).

Recent Accounting Pronouncements

No new accounting standards were adopted during the nine months ended September 30, 2024. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”), as noted below:

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements must be applied retrospectively to all prior periods presented in the financial statements. The effective date for the standard is for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, to provide more detailed income tax disclosure requirements. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.


11
Table of Contents
3. Revenue

Revenue Recognition and Product Sales, Net

The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, MACI Arthro instruments, Epicel grafts, and NexoBrid following the five-step model in Accounting Standards Codification 606, Revenue Recognition.

MACI Biopsy Kits

MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates set forth in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the treating surgeon to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.

MACI Arthro Instruments

MACI Arthro instruments are sold directly to hospitals and ambulatory surgical centers based upon rates set forth in price lists. The Company recognizes revenue from the sale of MACI Arthro instruments upon delivery of the instruments, at which time the customer (the facility) is in control of the instruments. MACI Arthro instruments can be used by an orthopedic surgeon to deliver MACI to a treated patient using an arthroscopic approach. The customer’s order of a MACI implant is separate from the process of ordering the MACI Arthro instruments. Therefore, the sale of the MACI Arthro instruments and any sale of implants are distinct and are accounted for separately.

MACI Implants

The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays each specialty pharmacy a fee in each instance when it dispenses MACI for use in treating a patient. Both Orsini and AllCare perform collection activities to collect payment from customers. In addition, the Company sells MACI directly to hospitals pursuant to an agreed upon purchase order and to a distributor, DMS Pharmaceutical Group, Inc. (“DMS”) at a contracted rate for the treatment of patients at military facilities throughout the U.S. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure that complete and correct billing information is provided to the insurers and hospitals.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of a MACI implant to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration.

When the Company sells MACI through its specialty pharmacies, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of September 30, 2024. The total allowance for uncollectible consideration as of September 30, 2024 and December 31, 2023 was $4.8 million and $5.6 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.4 million decrease or increase in the revenue recognized for the nine months ended September 30, 2024.
12
Table of Contents

Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior period.

Epicel

The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital.

NexoBrid

The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020, the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of September 30, 2024, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

In December 2022, the FDA approved a BLA for NexoBrid, granting a license for its commercial use in the U.S. NexoBrid is a topically-administered biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. In August 2024, the FDA additionally approved NexoBrid for pediatric use.

The Company sells NexoBrid to specialty distributors. These customers subsequently resell NexoBrid to hospitals and burn centers. Product revenue is recorded net of reserves for specialty distributor fees, prompt payment or other discounts and allowances for returns, as applicable. The Company recognizes product revenue from sales of NexoBrid when the specialty distributors take control of the product, which typically occurs upon delivery to the specialty distributors.
13
Table of Contents
Revenue by Product and Customer

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended September 30,Nine Months Ended September 30,
Revenue by product (in thousands) 2024202320242023
MACI implants, kits, and instruments
Implants based on contracted rate sold through a specialty pharmacy (a)
$31,637 $22,598 $90,246 $68,220 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
3,473 5,030 10,160 13,526 
Implants sold direct based on contracted rates (c)
6,968 5,797 21,465 19,932 
Implants sold direct subject to third-party reimbursement (d)
1,083 1,432 3,227 2,974 
Biopsy kits and instruments - direct bill469 457 1,530 1,517 
Change in estimates related to prior periods (e)
1,026 2,275 2,345 1,945 
Total MACI implants, kits, and instruments44,656 37,589 128,973 108,114 
Epicel
Direct bill (hospital)12,184 7,394 30,606 23,808 
NexoBrid (f)
1,065 598 2,269 598 
Total revenue$57,905 $45,581 $161,848 $132,520 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents U.S. commercial revenue of NexoBrid.
4. Selected Balance Sheet Components

Inventory

Inventory consisted of the following:
(In thousands)September 30, 2024December 31, 2023
Raw materials$11,854 $11,348 
Work-in-process1,850 1,210 
Finished goods2,052 529 
Total inventory$15,756 $13,087 





14
Table of Contents
Property and Equipment

Property and Equipment, net consisted of the following:

(In thousands)September 30, 2024December 31, 2023
Machinery and equipment$5,901 $5,562 
Furniture, fixtures and office equipment1,647 1,731 
Computer equipment and software9,972 9,116 
Leasehold improvements15,927 14,901 
Construction in process80,544 32,531 
Total property and equipment, gross113,991 63,841 
Less accumulated depreciation(25,578)(22,206)
Total property and equipment, net$88,413 $41,635 

Depreciation expense for the three and nine months ended September 30, 2024 was $1.2 million and $3.5 million, respectively, and $1.0 million and $3.0 million, respectively, for the same periods in 2023.

Intangible Assets

Intangible assets, net consisted of the following:

September 30, 2024December 31, 2023
(In thousands)Useful Life (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(1,094)$6,406 $7,500 $(625)$6,875 

Amortization expense for the three and nine months ended September 30, 2024 was $0.2 million and $0.5 million, respectively, and $0.2 million and $0.5 million, respectively, for the same periods in 2023.

Future amortization expense of intangible assets as of September 30, 2024 is estimated to be as follows:

(In thousands)Amount
Remainder of 2024$156 
2025625 
2026625 
2027625 
2028625 
Thereafter3,750 
Total$6,406 

Accrued Expenses

Accrued Expenses consisted of the following:
(In thousands)September 30, 2024December 31, 2023
Bonus-related compensation$7,580 $9,757 
Employee-related accruals3,087 3,503 
Insurance reimbursement-related liabilities3,336 3,591 
Other accrued expenses340 364 
Total accrued expenses$14,343 $17,215 


15
Table of Contents
5. Leases

The Company leases facilities in Ann Arbor, Michigan, Cambridge, Massachusetts and Burlington, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases offsite warehouse space and other computer-related equipment.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”), which is currently being constructed. Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding, into an escrow account maintained by the escrow agent, a portion of its share of tenant improvement construction costs at the facility, which are designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. The Company funded the remaining 50% of its required cost amount, or approximately $28.3 million, with cash on hand, pursuant to the Construction Escrow Agreement in April 2024.

The term of the Burlington Lease began on June 1, 2023 (the “Commencement Date”), when the Company gained control of and commenced tenant improvement work at the Premises. The Company’s obligation to pay rent for the Premises began on July 1, 2024 (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million. The tenant improvement allowance is being used towards the design and construction of the tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company was not involved in the initial construction of the core and shell of the building. On June 1, 2023, the Company gained control of the Premises to begin construction of its tenant improvements. As such, the corresponding right-of-use asset and lease liability of $35.5 million was recorded on the Company’s condensed consolidated balance sheet. As there was not an implicit rate within the lease available, the Company estimated the incremental borrowing rate of 7.7%, based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The lease term of 13.1 years does not include the lease extension option, as the Company is not reasonably certain to exercise that option. The Company has determined that certain improvements to the Premises are landlord-owned improvements and costs incurred for these improvements are accounted for as a variable lease payment. In the nine months ended September 30, 2024, the Company recorded a right-of-use asset related to landlord-owned improvements incurred of approximately $3.6 million.

In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three and nine months ended September 30, 2024 and 2023, lease expense of less than $0.1 million was recorded related to short-term leases. For the three and nine months ended September 30, 2024, the Company recognized $3.2 million and $9.6 million, respectively, of operating lease expense and $3.2 million and $7.1 million, respectively, for the same period in 2023. For the three and nine months ended September 30, 2023, the Company recognized less than $0.1 million of financing lease expense.





16
Table of Contents
Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationSeptember 30, 2024December 31, 2023
Assets
OperatingRight-of-use assets$71,561 $73,462 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$6,119 $6,187 
Non-current
OperatingOperating lease liabilities$91,344 $81,856 
Total leased liabilities$97,463 $88,043 

6. Investments

Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:

September 30, 2024
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$5,543 $3 $— $— $5,546 
Corporate notes68,255 365 (15)— 68,605 
U.S. government agency bonds6,791 7 (1)— 6,797 
$80,589 $375 $(16)$— $80,948 
Classified as:
Short-term investments$48,053 
Long-term investments32,895 
$80,948 

December 31, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$3,638 $1 $— $— $3,639 
Corporate notes47,228 — (69)— 47,159 
U.S. government securities983 — — — 983 
U.S. government agency bonds14,003 — (32)— 13,971 
$65,852 $1 $(101)$— $65,752 
Classified as:
Short-term investments$40,469 
Long-term investments25,283 
$65,752 

As of September 30, 2024 and December 31, 2023, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three and nine months ended September 30, 2024 and 2023.

17
Table of Contents
7. Fair Value Measurements

The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2023 to September 30, 2024.

The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 September 30, 2024December 31, 2023
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$29,333 $29,333 $— $— $34,672 $34,672 $— $— 
Commercial paper (a)
5,546 — 5,546 — 4,876 — 4,876 — 
Corporate notes68,605 — 68,605 — 47,159 — 47,159 — 
U.S. government agency bonds6,797 — 6,797 — 13,971 — 13,971 — 
U.S. government securities (a)
15,904 — 15,904 — 24,874 — 24,874 — 
$126,185 $29,333 $96,852 $— $125,552 $34,672 $90,880 $— 

(a) Approximately $15.9 million of U.S. government securities as of September 30, 2024, and approximately $23.9 million of U.S. government securities and $1.2 million of commercial paper as of December 31, 2023, had an original maturity of 90 days or less and is recorded as a cash equivalent.

The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost, which approximates fair value.

8. Revolving Credit Agreement

On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.

Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.

The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit
18
Table of Contents
Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of September 30, 2024, there are no outstanding borrowings under the Revolving Credit Agreement.

The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).

The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness; (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).

9. Stock-Based Compensation

The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (collectively the “Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.

Stock Compensation Expense

Non-cash stock-based compensation expense (service-based stock options, restricted stock units and the employee stock purchase plan) is summarized in the following table:
 Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)2024202320242023
Cost of product sales$762 $660 $2,914 $2,341 
Research and development1,095 892 3,281 2,862 
Selling, general and administrative7,367 6,372 22,383 20,213 
Total non-cash stock-based compensation expense$9,224 $7,924 $28,578 $25,416 

Service-Based Stock Options

During the three and nine months ended September 30, 2024, the Company granted service-based options to purchase common stock of 105,025 and 745,412, respectively, and 58,500 and 594,217, respectively, for the same periods in 2023. The weighted-average grant-date fair value of service-based options granted during the three and nine months ended September 30, 2024 was $27.73 and $28.08 per option, respectively, and $22.36 and $18.80, respectively, for the same periods in 2023.

Restricted Stock Units

During the three and nine months ended September 30, 2024, the Company granted 35,610 and 622,535 restricted stock units, respectively, and 23,520 and 552,841, respectively, for the same periods in 2023. The weighted-average grant-date fair value of restricted stock units granted during the three and nine months ended September 30, 2024 was $47.59 and $48.19 per unit, respectively, and $36.51 and $30.24, respectively, for the same periods in 2023.

19
Table of Contents
10. Net Loss Per Common Share

A summary of net loss per common share is presented below:
 Three Months Ended September 30,Nine Months Ended September 30,
(Amounts in thousands, except per share amounts)2024202320242023
Net loss$(901)$(3,660)$(9,445)$(16,175)
   
Basic weighted-average common shares outstanding49,085 47,649 48,639 47,537 
Effect of dilutive stock options and restricted stock units— — — — 
Diluted weighted-average common shares outstanding49,085 47,649 48,639 47,537 
Basic loss per common share$(0.02)$(0.08)$(0.19)$(0.34)
Diluted loss per common share$(0.02)$(0.08)$(0.19)$(0.34)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,115 6,859 6,115 6,859 
Restricted stock units1,142 943 1,142 943 

11. NexoBrid License and Supply Agreements

On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological orphan product containing proteolytic enzymes, for which the FDA approved a BLA in December 2022 permitting the product’s use for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. Subsequently, in August 2024, the FDA approved a supplemental BLA expanding NexoBrid’s indication to include pediatric patients.

Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.

In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. The FDA’s December 2022 approval of NexoBrid resulted in the achievement of a $7.5 million regulatory milestone payment pursuant to the terms of the license agreement. The Company recorded the $7.5 million milestone for the licensing rights to commercially sell NexoBrid in the U.S. as an intangible asset as of December 31, 2022. The $7.5 million milestone payment was paid to MediWound in February of 2023.

Additionally, the Company is obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to NexoBrid in North America exceed $75.0 million. As of September 30, 2024, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also pays MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound is manufacturing, and will continue to manufacture, NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. After the initial term, the Company may extend the supply agreement on an annual basis for up to 10 additional years, at its sole discretion. Under the supply agreement, the Company is permitted to establish an alternate source of supply in certain circumstances, including the event of a supply failure.

Additionally, beginning in 2020, BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound was completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company received a percentage of gross profit for sales directly to
20
Table of Contents
BARDA. As of September 30, 2024, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

12. Commitments and Contingencies

From time-to-time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of September 30, 2024, the Company had no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

21
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company and a leading provider of advanced therapies for the sports medicine and severe burn care markets. Whether we are treating damaged cartilage or severe burns, we provide advanced therapies to repair serious injuries and restore lives. Our highly differentiated portfolio of cell therapy and specialty biologic products combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® is a permanent skin replacement Humanitarian Use Device (“HUD”) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). We also hold an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid® (anacaulase-bcdb), a topically-administered biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

The Ongoing Military Conflicts in the Middle East

In May 2019, we entered into exclusive license and supply agreements with MediWound, under which MediWound manufactures and supplies NexoBrid to the U.S. market on a unit price basis. MediWound develops and manufactures NexoBrid, in part, at its facilities in Yavne, Israel.

We continue to monitor the ongoing military conflicts in the Middle East region involving Israel, and we are in close communication with MediWound leadership. MediWound’s NexoBrid manufacturing operations are continuing and, as of the date of this disclosure, MediWound does not anticipate a material disruption to its ongoing supply of commercial NexoBrid to the United States. To the extent the conflicts in the Middle East region intensify or expand to include additional countries or militant groups and MediWound’s facilities in Israel are damaged or destroyed, travel to and from Israel is halted or inhibited, or significant key MediWound operational personnel are called to military service, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted. As of the date of this report, we maintain an ample supply of NexoBrid at our U.S.-based third-party logistics provider.

Manufacturing

We have a cell manufacturing facility in Cambridge, Massachusetts, which is used for U.S. manufacturing and distribution of MACI and Epicel. The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel. Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain, are sourced from Taiwan.

Product Portfolio

Our marketed products include two FDA-approved autologous cell therapies and one FDA-approved specialty biologic product. MACI is a third-generation autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Both autologous cell therapy products are currently manufactured and marketed in the U.S. NexoBrid is a topically-administered biological orphan product containing proteolytic enzymes that is indicated for eschar removal in adult and pediatric patients with deep partial-thickness and/or full-thickness burns. We hold exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.


22
Table of Contents
MACI

MACI is a third-generation autologous chondrocyte implantation (“ACI”) product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Our target audiences are orthopedic surgeons who self-identify and/or have formal specialty training in sports medicine, and a subpopulation of general orthopedic surgeons who perform a high volume of cartilage repair procedures involving the knee. Our MACI commercial team consists of individual sales representatives that regularly engage with our target audience. The team is divided into geographic regions, each managed by a Regional Sales Director and led by a Senior Vice President of Sales. Most private payers have a medical policy that covers treatment with MACI with the top 30 largest commercial payers having a formal medical policy for MACI or ACI in general. With respect to private commercial payers that have not yet approved a medical policy for MACI, we often obtain approval on a case-by-case basis.

MACI consists of autologous cultured chondrocytes, which are human-derived cells that are obtained from the patient’s own cartilage, and which are seeded onto resorbable Type I/III collagen membrane. Since MACI’s commercial launch, a treating surgeon has been able to use MACI to treat a patient through an open surgical procedure. In August 2024, however, the FDA approved a supplemental Biologics License Application (“sBLA”) expanding the MACI indication to add instructions for the arthroscopic delivery of MACI to the product’s approved labeling, permitting the repair of single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size via that approach. MACI ArthroTM provides a less invasive technique compared to the current approach and allows surgeons to evaluate, prepare and treat the cartilage defect, and deliver the MACI implant, under direct arthroscopic visualization using specialized and custom-designed instruments (the “MACI Arthro instruments”) through small incisions or portals. The arthroscopic delivery of MACI could increase the ease of MACI’s use for physicians and may reduce both the length of the procedure as well as procedure-induced trauma, ultimately resulting in a reduction of a patient’s post-operative pain and accelerating a patient’s recovery. MACI Arthro became commercially available in the United States during the third quarter of 2024 and we began selling the MACI Arthro instruments at that time. In conjunction with the launch of MACI Arthro, we have expanded our target surgeon base from 5,000 to 7,000 to include orthopedic surgeons that perform high volumes of knee cartilage repair surgeries, predominantly through arthroscopic procedures.

We also are evaluating the feasibility and potential market opportunity involved in delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion for MACI will require conducting an additional randomized clinical trial concerning the product’s use in the ankle and we are on track to initiate a MACI Ankle clinical trial beginning in 2025. If approved, we believe MACI’s expansion into the ankle will be a significant long-term growth driver for the product, beginning in the latter half of the decade.

Epicel

Epicel is a permanent skin replacement for deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Epicel is regulated by the Center for Biologics Evaluation and Research (“CBER”) of the FDA under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns in both adult and pediatric patients. Epicel was designated as a HUD in 1998 and a Humanitarian Device Exemption (“HDE”) application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S., and certain HUDs are restricted by the amount which a manufacturer may charge for its use.

Epicel is not price-restricted in this manner because on February 18, 2016, the FDA approved our HDE supplement to revise the labeled indications of use for Epicel to specifically include pediatric patients, thus allowing Epicel to be sold for profit. The revised product label also now specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a physician-sponsored study comparing outcomes in patients with large burns treated with Epicel relative to standard care.

NexoBrid

Our portfolio of commercial-stage products also includes NexoBrid (anacaulase-bcdb), a topically-administered biological orphan product containing proteolytic enzymes, for which the FDA approved a BLA in December 2022 permitting the product’s use for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. Subsequently, in August 2024, the FDA approved a sBLA expanding NexoBrid’s indication to include pediatric patients.

23
Table of Contents
NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets. NexoBrid has the potential to change the standard of care for eschar removal with respect to hospitalized burn patients and treat a significant addressable market in the U.S. With respect to NexoBrid, of the approximately 40,000 people that are hospitalized in the U.S. each year for burn-related injuries, the majority, over 30,000, have thermal burns and will likely require some level of eschar removal. NexoBrid’s FDA approval expands our burn care franchise’s total addressable market, which will permit us to treat a significantly larger segment of hospitalized burn patients than with Epicel alone. The expansion of our target addressable market supports a broader commercial footprint, and we believe that this may help drive both increased NexoBrid use as well as increased Epicel awareness throughout the burn care space. Both our Epicel and NexoBrid products are serviced by our burn care field force, which consists of individual sales and clinical representatives that regularly engage with our target audience. The team is divided into geographical regions, each managed by a Regional Sales Director and led by a Vice President of National Burn Care Sales.

In May 2019, we entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel. Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain are sourced from Taiwan.

Results of Operations

The following is a summary of our condensed consolidated results of operations:
 Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20242023Change $Change %20242023Change $Change %
Total revenue$57,905 $45,581 $12,324 27.0 %$161,848 $132,520 $29,328 22.1 %
Cost of product sales16,252 14,973 1,279 8.5 %48,240 45,451 2,789 6.1 %
Gross profit41,653 30,608 11,045 36.1 %113,608 87,069 26,539 30.5 %
Research and development6,093 5,676 417 7.3 %19,874 16,141 3,733 23.1 %
Selling, general and administrative38,025 29,989 8,036 26.8 %107,694 90,123 17,571 19.5 %
Total operating expenses44,118 35,665 8,453 23.7 %127,568 106,264 21,304 20.0 %
Loss from operations(2,465)(5,057)2,592 (51.3)%(13,960)(19,195)5,235 (27.3)%
Total other income1,564 1,111 453 40.8 %4,515 2,734 1,781 65.1 %
Income tax benefit— (286)286 (100.0)%— (286)286 (100.0)%
Net loss$(901)$(3,660)$2,759 (75.4)%$(9,445)$(16,175)$6,730 (41.6)%

Comparison of the Periods Ended September 30, 2024 and 2023

Total Revenue

Revenue by product is as follows:

 Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20242023Change $Change %20242023Change $Change %
MACI$44,656 $37,589 $7,067 18.8 %$128,973 $108,114 $20,859 19.3 %
Epicel12,184 7,394 4,790 64.8 %30,606 23,808 6,798 28.6 %
NexoBrid1,065 598 467 78.1 %2,269 598 1,671 279.4 %
Total revenue$57,905 $45,581 $12,324 27.0 %$161,848 $132,520 $29,328 22.1 %

24
Table of Contents
Total revenue increase for the three and nine months ended September 30, 2024, compared to the same periods in 2023, was driven primarily by MACI volume and price growth, in addition to burn care revenue from higher Epicel and NexoBrid volume.

Seasonality

Sales of MACI implants have historically experienced a level of seasonality throughout the year. In the last five years through 2023, MACI sales volumes from the first through the fourth quarter on average represented 20% (18%-22% range), 22% (16%-24% range), 23% (21%-26% range) and 35% (33%-38% range) respectively, of total annual volumes. Historically, MACI orders are normally stronger in the fourth quarter due to several factors including the satisfaction by patients of insurance deductible limits and the time of year patients prefer to start rehabilitation. Due to the low incidence and variable occurrence of severe burns encompassing a large total body surface area, Epicel revenue has inherent variability from quarter-to-quarter and does not exhibit significant seasonality. Although U.S. sales of NexoBrid only began in September 2023, and we are still relatively early in its commercial launch, we do not expect NexoBrid revenue to experience significant seasonality given its emergent use in treating severe burns.

Gross Profit

Gross profit increase for the three and nine months ended September 30, 2024, compared to the same periods in 2023, was driven by revenue growth across all products, combined with our primarily fixed manufacturing cost structure which consists mainly of labor and facility costs.

Research and Development Expenses

The following table summarizes research and development expenses, which include materials, professional fees and an allocation of employee-related salary and fringe benefit costs for our research and development projects:

 Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20242023Change $Change %20242023Change $Change %
MACI$4,345 $4,020 $325 8.1 %$14,635 $10,412 $4,223 40.6 %
Epicel1,138 890 248 27.9 %3,463 2,975 488 16.4 %
NexoBrid610 766 (156)(20.4)%1,776 2,754 (978)(35.5)%
Total research and development expenses$6,093 $5,676 $417 7.3 %$19,874 $16,141 $3,733 23.1 %

Research and development expenses increased for the three months ended September 30, 2024, compared to the same period in 2023. The increase is primarily due to higher headcount and employee expenses.

Research and development expenses increased for the nine months ended September 30, 2024, compared to the same period in 2023. The increase is primarily due to higher headcount and employee expenses, as well as increased MACI arthroscopic development program costs in 2024.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended September 30, 2024 were $38.0 million, compared to $30.0 million for the same period in 2023. The increase in selling, general and administrative expenses was primarily due to higher headcount and employee expenses, including stock compensation and sales incentive compensation, and an increase in marketing programs and events, including to support the MACI arthroscopic launch.

Selling, general and administrative expenses for the nine months ended September 30, 2024 were $107.7 million, compared to $90.1 million for the same period in 2023. The increase in selling, general and administrative expenses was primarily due to higher headcount and employee expenses, including stock compensation and sales incentive compensation, an increase in marketing programs and events, including to support the MACI arthroscopic launch, and the lease expense associated with the Burlington Lease.


25
Table of Contents
Total Other Income 

The increase in other income for the three and nine months ended September 30, 2024, compared to the same periods in 2023 was due to an increase in interest income primarily due to fluctuations in the rates of return on our investments in various marketable debt securities and money market funds.

Stock-based Compensation Expense

Non-cash stock-based compensation expense is summarized in the following table: 

 Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)20242023Change $Change %20242023Change $Change %
Cost of product sales$762 $660 $102 15.5 %$2,914 $2,341 $573 24.5 %
Research and development1,095 892 203 22.8 %3,281 2,862 419 14.6 %
Selling, general and administrative7,367 6,372 995 15.6 %22,383 20,213 2,170 10.7 %
Total non-cash stock-based compensation expense$9,224 $7,924 $1,300 16.4 %$28,578 $25,416 $3,162 12.4 %

The increase in stock-based compensation expense for the three and nine months ended September 30, 2024, compared to the same periods in 2023, was due primarily to fluctuations in stock prices and the mix of service-based options and restricted stock units, which impacts the fair value of the options and restricted stock units awarded and the expense recognized in the period.

Liquidity and Capital Resources

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

Nine Months Ended September 30,
(In thousands)20242023
Net cash provided by operating activities$35,921 $25,225 
Net cash (used in) provided by investing activities(64,383)4,958 
Net cash provided by financing activities11,946 2,311 
Net (decrease) increase in cash, cash equivalents, and restricted cash$(16,516)$32,494 

Net Cash Provided by Operating Activities

Our cash, cash equivalents and restricted cash totaled $70.4 million, short-term investments totaled $48.1 million and long-term investments totaled $32.9 million as of September 30, 2024. The $35.9 million of cash provided by operations during the nine months ended September 30, 2024 was primarily the result of non-cash charges of $28.6 million related to stock-based compensation expense, $5.1 million of operating lease amortization and $4.0 million in depreciation and amortization expense, offset by a net loss of $9.4 million and a net increase of $7.8 million related to movements in our working capital accounts. The overall increase in cash from our working capital accounts was primarily driven by a decrease in accounts receivable due to cash collections and receipts of tenant improvement allowances which exceeded payments on operating leases amortization, offset by a decrease in accounts payable and accrued expenses due to timing of payments and an increase in inventory primarily related to supporting NexoBrid commercial availability.

Our cash, cash equivalents and restricted cash totaled $83.6 million, short-term investments totaled $44.9 million and long-term investments totaled $20.2 million as of September 30, 2023. The $25.2 million of cash provided by operations during the nine months ended September 30, 2023 was primarily the result of non-cash charges of $25.4 million related to stock-based compensation expense, $4.3 million of operating lease amortization and $3.5 million in depreciation and amortization expense, offset by a net loss of $16.2 million and a net increase of $8.8 million related to movements in our working capital accounts. The overall increase in cash from our working capital accounts was primarily driven by a decrease in accounts receivable due to
26
Table of Contents
cash collections and receipts of tenant improvement allowances, offset by a decrease in accrued expenses due to timing of payments.

Net Cash (Used In) Provided By Investing Activities

Net cash used in investing activities during the nine months ended September 30, 2024 was the result of $52.6 million in investment purchases and $50.2 million of property and equipment purchases primarily for construction in process related to the Burlington Lease, offset by $38.4 million of investment sales and maturities.

Net cash provided by investing activities during the nine months ended September 30, 2023 was the result of $60.9 million of investment sales and maturities, offset by $36.3 million in investment purchases, a $7.5 million regulatory milestone payment to MediWound resulting from the FDA’s approval of the NexoBrid BLA, and $12.2 million of property and equipment purchases primarily for manufacturing upgrades and construction in process related to the Burlington Lease.

Net Cash Provided by Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2024 was the result of net proceeds from the exercise of stock options and the employee stock purchase plan of $17.3 million, partially offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $5.3 million.

Net cash provided by financing activities during the nine months ended September 30, 2023 was the result of net proceeds from the exercise of stock options and purchases under the employee stock purchase plan of $4.6 million, partially offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $2.3 million.

Liquidity

Since our acquisition of MACI and Epicel in 2014, our primary focus has been to invest in our existing commercial business with the goal of growing revenue. We have raised significant funds in order to advance and complete our product development and product life-cycle management programs and to market and commercialize our products, including NexoBrid. To date, we have financed our operations primarily through cash received through MACI, Epicel and NexoBrid sales, debt, and public and private sales of our equity securities. In the future, we may finance our operations through the sales of equity securities, revolver borrowings or other debt financings, in addition to cash generated from operations.

We believe that our current cash on hand, cash equivalents, investments, and available borrowing capacity will be sufficient to support our current operations through at least 12 months from the issuance of the condensed consolidated financial statements included in this report. Our actual cash requirements may differ from projections and will depend on many factors, including the level and pace of future research and development efforts, the scope and results of ongoing and potential clinical trials, the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, global macroeconomic conditions, costs associated with possible acquisitions or development of complementary business activities, and the cost to market our products.

As of September 30, 2024, we were not party to any off-balance sheet arrangements.

Sources of Capital

On July 29, 2022, we entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). We have no immediate plans to borrow under the Revolving Credit Agreement, but we may use the facility for working capital needs and other general corporate purposes. As of September 30, 2024, there are no outstanding borrowings under the Revolving Credit Agreement, and we are in compliance with all applicable covenant requirements. See Note 8, “Revolving Credit Agreement” in the accompanying condensed consolidated financial statements for further details.

Contractual Obligations and Commitments

The disclosure of our contractual obligations and commitments is set forth in the heading “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2023. In connection with the Burlington Lease, the Company funded the remaining 50% of its required cost amount, or approximately $28.3 million, with cash on hand, pursuant to the Construction Escrow Agreement in
27
Table of Contents
April 2024. There have been no other material changes, outside of the ordinary course of business, to our contractual obligations and commitments since December 31, 2023.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, expenses, and related disclosures. Actual results may differ materially from these estimates under different assumptions and conditions.

There have been no material changes to our critical accounting policies and estimates in the nine months ended September 30, 2024. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, 2023.

Cautionary Note Regarding Forward-Looking Statements

This report, including the documents incorporated by reference herein, contains certain statements that describe our management’s beliefs concerning future business conditions, plans and prospects, growth opportunities and the outlook for our business based upon information currently available. Such statements are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Wherever possible, we have identified these forward-looking statements by words such as “will,” “may,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “projects,” “trends,” “opportunity,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “target,” “achieve,” “continuing,” “ongoing,” and similar words or phrases, or future or conditional verbs such as “would,” “should,” “could,” “may,” or similar expressions. Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI®, MACI Arthro™, Epicel®, and NexoBrid®, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts, the ability to achieve or sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, surgeon adoption of MACI Arthro, physician and burn center adoption of NexoBrid, labor strikes, changes in surgeon and hospital treatment prioritizations caused by the temporary shortage of essential medical supplies, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to the ongoing military conflicts in the Middle East region involving Israel, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine and the Middle East conflicts, adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, global geopolitical tensions or record inflation and potential future impacts on our business or the economy generally stemming from a public health emergency. These forward-looking statements are based upon assumptions our management believes are reasonable. Such forward-looking statements are subject to risks and uncertainties, which could cause our actual results, performance and achievements to differ materially from those expressed in, or implied by, these statements, including, among others, the risks and uncertainties listed in our Annual Report on Form 10-K under “Part I, Item 1A Risk Factors.”

Because our forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different and any or all of our forward-looking statements may turn out to be wrong. Forward-looking statements speak only as of the date made and can be affected by assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in our Annual Report on Form 10-K will be important in determining future results. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. Consequently, we cannot assure you that our expectations or forecasts expressed in such forward-looking statements will be achieved. Except as required by law, we undertake no obligation to publicly update any of our forward-looking or other statements, whether as a result of new information, future events, or otherwise.


28
Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, see Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2023. Our exposures to market risk have not changed materially since December 31, 2023.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its Certifying Officers), evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation as of September 30, 2024, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2024, there were no material changes made in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act).

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not party to any material legal proceedings, although from time to time we may become involved in disputes in connection with the operation of our business.

Item 1A. Risk Factors

Factors that could cause the Company’s actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.


29
Table of Contents
Item 5. Other Information

Rule 10b5-1 Trading Plans

During the three months ended September 30, 2024, none of the Company’s Section 16 officers or directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).

Additionally, there were no “non-Rule 10b5-1 trading arrangements” (as defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the three months ended September 30, 2024 by our Section 16 officers or directors.
30
Table of Contents
Item 6. Exhibits

The Exhibits listed in the Exhibit Index are filed as a part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

Incorporated by Reference
Exhibit NumberDescription of ExhibitsFormFile NumberExhibitFiling Date
3.18-K000-220254.1December 17, 2009
3.2S-1333-1600443.2March 31, 2010
3.38-K000-220253.1March 25, 2011
3.48-K001-352803.1November 24, 2014
3.58-K000-220253.1November 12, 2010
4.110-K001-352804.5February 25, 2020
31.1*
31.2*
32.1*
10.1†*
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
104*

* Filed herewith.
† Certain immaterial and confidential portions of this exhibit have been omitted in accordance with Item 601 (a)(5) of Regulation S-K.
31
Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: November 7, 2024
 
 VERICEL CORPORATION
  
  
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
  
  
 /s/ JOSEPH A. MARA
 Joseph A. Mara
 Chief Financial Officer
 (Principal Financial Officer)


32